Kbc Group Nv Supernus Pharmaceuticals, Inc. Transaction History
Kbc Group Nv
- $37 Billion
- Q2 2025
A detailed history of Kbc Group Nv transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 1,774 shares of SUPN stock, worth $91,520. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,774
Previous 2,679
33.78%
Holding current value
$91,520
Previous $88,000
36.36%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding SUPN
# of Institutions
316Shares Held
61.2MCall Options Held
18.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$536 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$320 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$248 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$156 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$142 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.76B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...